BIOMAT Database Logo BIOMAT Database Logo

[Highly active antiretroviral therapy (HAART)]. 1998

W Steflitsch
Pulmologisches Zentrum Wein.

UI MeSH Term Description Entries
D010349 Patient Compliance Voluntary cooperation of the patient in following a prescribed regimen. Client Adherence,Client Compliance,Non-Adherent Patient,Patient Adherence,Patient Cooperation,Patient Noncompliance,Patient Non-Adherence,Patient Non-Compliance,Patient Nonadherence,Therapeutic Compliance,Treatment Compliance,Adherence, Client,Adherence, Patient,Client Compliances,Compliance, Client,Compliance, Patient,Compliance, Therapeutic,Compliance, Treatment,Cooperation, Patient,Non Adherent Patient,Non-Adherence, Patient,Non-Adherent Patients,Non-Compliance, Patient,Nonadherence, Patient,Noncompliance, Patient,Patient Non Adherence,Patient Non Compliance,Patient, Non-Adherent,Therapeutic Compliances,Treatment Compliances
D004338 Drug Combinations Single preparations containing two or more active agents, for the purpose of their concurrent administration as a fixed dose mixture. Drug Combination,Combination, Drug,Combinations, Drug
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D015658 HIV Infections Includes the spectrum of human immunodeficiency virus infections that range from asymptomatic seropositivity, thru AIDS-related complex (ARC), to acquired immunodeficiency syndrome (AIDS). HTLV-III Infections,HTLV-III-LAV Infections,T-Lymphotropic Virus Type III Infections, Human,HIV Coinfection,Coinfection, HIV,Coinfections, HIV,HIV Coinfections,HIV Infection,HTLV III Infections,HTLV III LAV Infections,HTLV-III Infection,HTLV-III-LAV Infection,Infection, HIV,Infection, HTLV-III,Infection, HTLV-III-LAV,Infections, HIV,Infections, HTLV-III,Infections, HTLV-III-LAV,T Lymphotropic Virus Type III Infections, Human
D019380 Anti-HIV Agents Agents used to treat AIDS and/or stop the spread of the HIV infection. These do not include drugs used to treat symptoms or opportunistic infections associated with AIDS. AIDS Drug,AIDS Drugs,Anti-AIDS Agents,Anti-AIDS Drug,Anti-HIV Agent,Anti-HIV Drug,Anti-AIDS Drugs,Anti-HIV Drugs,Agent, Anti-HIV,Agents, Anti-AIDS,Agents, Anti-HIV,Anti AIDS Agents,Anti AIDS Drug,Anti AIDS Drugs,Anti HIV Agent,Anti HIV Agents,Anti HIV Drug,Anti HIV Drugs,Drug, AIDS,Drug, Anti-AIDS,Drug, Anti-HIV,Drugs, AIDS,Drugs, Anti-AIDS,Drugs, Anti-HIV

Related Publications

W Steflitsch
Change of HAART. Highly active antiretroviral therapy.
May 1999, Lancet (London, England),
W Steflitsch
Spontaneous apoptosis and highly active antiretroviral therapy (HAART).
February 2000, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie,
W Steflitsch
Gynaecomastia associated with highly active antiretroviral therapy (HAART).
January 2010, Journal of radiology case reports,
W Steflitsch
Thymidine analogue-sparing highly active antiretroviral therapy (HAART).
February 2003, Journal of HIV therapy,
W Steflitsch
[HIV associated encephalopathy after highly active antiretroviral therapy (HAART)].
April 2004, No to shinkei = Brain and nerve,
W Steflitsch
HIV and HAART in 1997. Highly active antiretroviral therapy.
August 1997, The Nurse practitioner,
W Steflitsch
[HIV-infection, HAART (highly-active antiretroviral therapy) and hyperlipidemia].
May 2003, Deutsche medizinische Wochenschrift (1946),
W Steflitsch
The rules for successful HAART (highly active antiretroviral therapy).
January 1998, Newsline (People with AIDS Coalition of New York),
W Steflitsch
Variations in patterns of highly active antiretroviral therapy (HAART) adherence.
September 2005, AIDS and behavior,
W Steflitsch
[HIV: no virus eradication with HAART. Highly active antiretroviral therapy].
February 2000, Deutsche medizinische Wochenschrift (1946),
Copied contents to your clipboard!